Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biontech Se ADR (BNTX)

Biontech Se ADR (BNTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,497,048
  • Shares Outstanding, K 241,521
  • Annual Sales, $ 550,960 K
  • Annual Income, $ 17,360 K
  • 60-Month Beta -1.58
  • Price/Sales 137.42
  • Price/Cash Flow 1,151.03
  • Price/Book 22.58
Trade BNTX with:

Options Overview

Details
  • Implied Volatility 81.15%
  • Historical Volatility 58.11%
  • IV Percentile 48%
  • IV Rank 31.81%
  • IV High 142.58% on 09/09/20
  • IV Low 52.50% on 04/09/21
  • Put/Call Vol Ratio 0.56
  • Today's Volume 2,407
  • Volume Avg (30-Day) 11,000
  • Put/Call OI Ratio 1.19
  • Today's Open Interest 135,645
  • Open Int (30-Day) 123,675

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 8.16
  • Number of Estimates 4
  • High Estimate 12.99
  • Low Estimate 3.89
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +2,042.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
194.04 +63.47%
on 07/08/21
328.70 -3.50%
on 07/29/21
+93.31 (+41.68%)
since 06/30/21
3-Month
145.00 +118.75%
on 05/06/21
328.70 -3.50%
on 07/29/21
+128.91 (+68.47%)
since 04/30/21
52-Week
54.10 +486.30%
on 09/04/20
328.70 -3.50%
on 07/29/21
+233.03 (+276.89%)
since 07/30/20

Most Recent Stories

More News
Stock Market News for Jul 29, 2021

U.S. stock markets closed mixed on Wednesday following the Fed's decision to keep interest rate near zero.

BA : 227.84 (-1.64%)
PFE : 42.85 (+0.14%)
ODFL : 268.50 (+0.19%)
BNTX : 319.65 (+2.26%)
Pfizer (PFE) Q2 Earnings Beat, View Up on COVID-19 Vaccine

Pfizer (PFE) beats second-quarter estimates for earnings and sales. It lifts its guidance for 2021.

BMY : 68.04 (-0.16%)
PFE : 42.85 (+0.14%)
AMGN : 241.58 (-0.36%)
BNTX : 319.65 (+2.26%)
Dyadic Int'l (DYAI) Inks Deal Toward Potential Access to 40% of the World as Covid Vaccine Continues in Development

NVAX : 182.92 (-0.59%)
MRNA : 355.06 (+2.73%)
PFE : 42.85 (+0.14%)
JNJ : 172.53 (+0.20%)
BNTX : 319.65 (+2.26%)
AZN : 57.33 (-0.54%)
IBB : 166.27 (+0.28%)
DYAI : 3.72 (+3.05%)
BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $286.26, marking a +1.53% move from the previous day.

BNTX : 319.65 (+2.26%)
Will Pfizer (PFE) Beat Expectations This Earnings Season?

Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the second quarter.

BMY : 68.04 (-0.16%)
PFE : 42.85 (+0.14%)
APTO : 2.70 (+3.45%)
BNTX : 319.65 (+2.26%)
Pfizer And BioNTech to Supply U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.

- Dose deliveries for new order expected to occur from October 2021 through April 2022

PFE : 42.85 (+0.14%)
BNTX : 319.65 (+2.26%)
Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine. These doses are expected...

PFE : 42.85 (+0.14%)
BNTX : 319.65 (+2.26%)
Pfizer (PFE) Inks Vaccine Deal, Faces FDA Delay on JAK Drugs

Pfizer (PFE) partners with Biovac for manufacturing and distributing its COVID-19 vaccine in African Union. The FDA delays decision on Pfizer's regulatory filings for JAK inhibitors.

PFE : 42.85 (+0.14%)
LLY : 244.83 (-0.20%)
ABBV : 116.95 (-1.62%)
BNTX : 319.65 (+2.26%)
Delta Variant Infections of COVID Rising Quickly & Now Responsible for 83% of All U.S. Cases

PALM BEACH, Fla., /PRNewswire/ -- According to WebMD, this week the nation's top health officials  Tuesday that the Delta variant of the coronavirus is racing through and other parts of the world...

BIOV.CN : 0.225 (+4.65%)
BVAXF : 0.1694 (-10.84%)
JNJ : 172.53 (+0.20%)
PFE : 42.85 (+0.14%)
BNTX : 319.65 (+2.26%)
MRNA : 355.06 (+2.73%)
SRNE : 8.32 (-0.83%)
Delta Means Beta Testing Alpha Strategies in Biotech (NVAX, MRNA, DYAI, PFE, JNJ, BNTX, AZN, IBB)

PFE : 42.85 (+0.14%)
JNJ : 172.53 (+0.20%)
BNTX : 319.65 (+2.26%)
AZN : 57.33 (-0.54%)
IBB : 166.27 (+0.28%)
NVAX : 182.92 (-0.59%)
DYAI : 3.72 (+3.05%)
MRNA : 355.06 (+2.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany.

See More

Key Turning Points

3rd Resistance Point 351.61
2nd Resistance Point 340.16
1st Resistance Point 326.37
Last Price 319.65
1st Support Level 301.13
2nd Support Level 289.68
3rd Support Level 275.89

See More

52-Week High 328.70
Last Price 319.65
Fibonacci 61.8% 223.80
Fibonacci 50% 191.40
Fibonacci 38.2% 159.00
52-Week Low 54.10

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar